Exxelia Ohmcraft Custom Resistors Enable Metabolic Analyses of Live Cell Cultures in Pharmaceutical Research
ROCHESTER, N.Y., April 9, 2020 — In the development of new pharmaceutical therapies, researchers conduct metabolic analyses of live cell cultures to understand the critical role of metabolism in a wide variety of diseases and conditions.
To do so, they must rely on life science research and diagnostic instruments with complex high gain amplifier circuits. Leading manufacturers of this type of equipment have partnered with Exxelia Ohmcraft to design custom, high-resistance surface mount resistors that are essential to the function of these circuits.
Specifically, oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) are two key indicators of mitochondrial respiration and glycolysis that provide a systems-level view of cellular metabolic function in cultured cells. The analyzer equipment conducts these measurements automatically.
“The accuracy and reliability of these tools are crucial to the researchers’ ability to make progress in their studies, which have the potential to change—and save—lives,” said Eric Van Wormer, Vice President of Exxelia Ohmcraft. “To meet the design needs of this particular application, we developed a custom resistor solution with a unique form factor and used special terminations to facilitate the manufacturability of the end product.”
Exxelia Ohmcraft’s technology utilizes the proprietary Micropen electronic printing system to “print” precise, narrow, serpentine lines with resistive ink on a ceramic substrate, producing higher performance resistors over a wider range of values on a smaller surface area than is possible with conventional film resistor technology.
HLD EUROPE ENTERS INTO EXCLUSIVE NEGOTIATIONS WITH IK INVESTMENT PARTNERS TO ACQUIRE EXXELIA
Exxelia develops and manufactures complex passive components and electromechanical solutions for niche industrial markets such as aeronautics, space, defense, medical and rail, where product reliability and performance are essential. The group addresses main institutional players, systems and equipment manufacturers. Exxelia offers a complete and custom product range (capacitors, inductors, resistors, filters, position sensors and rotary joints) embedded into a large number of programs: from the Airbus A350 to the Boeing Dreamliner, from the Ariane 6 launcher to satellite constellations (such as Galileo, Oneweb, etc.), from the Rafale to the F-35, from subway coaches to high-speed trains, from MRI medical equipment to defibrillators. With an expected proforma revenue of around 170 million euros for 2019 and around 2,000 employees, Exxelia is present today in more than 30 countries and operates in Europe and the United States, in Morocco and in Vietnam through its production sites, its design centers as well as its network of sales partners. Avec l’appui de son nouvel actionnaire, Exxelia pourra intensifier sa démarche d’excellence opérationnelle et d’innovation et poursuivre sa stratégie d’internationalisation avec la pénétration de marchés porteurs tels que l’Inde ou la Chine et accélérer son développement aux Etats-Unis. With the support of its new shareholder, Exxelia will be able to intensify its operational excellence and innovation efforts, pursue its internationalization strategy with the penetration of high-growth markets such as India or China, and accelerate its development in the United States. Paul Maisonnier, CEO of Exxelia: « I am delighted to embark on a new stage of development with our new shareholders, with whom we share the same vision. Together, we aim to strengthen Exxelia’s unique “one-stop-shop” by offering high-reliability custom products combined with a strong capacity for innovation. We will pursue our continuous improvement approach and our internationalization strategy to make Exxelia a world leader in our niche markets. In that regard, HLD's experience in international business development is precious to us. We thank IK Investment Partners for its total support over the past 5 years which has enabled us to set up a solid platform capable of supporting our ambitions for global growth, which we are delighted to continue with HLD ». Dan Soudry, Partner at IK Investment Partners: « As shareholders of Exxelia since 2015, we are very pleased to have supported the various stages of transformation and growth of the group, through a deep structuring phase led by the management team and an external growth strategy. This has strengthened the group's presence in the United States, especially with the acquisition of Raf Tabtronics, Deyoung, and Micropen, and diversified its expertise on new product lines ». Jean-Bernard Lafonta, Founding Partner of HLD Europe and Jean-Hubert Vial, Partner: « HLD supports successful companies with no restrictions on duration. We believe this specificity was important in the choice of Exxelia’s new shareholder: it is essential to achieve the ambition of growth while considering the long-term nature of Exxelia clients’ programs. We are delighted to be associated with the group's project, whose entrepreneurial culture echoes the entrepreneurial spirit that drives HLD. We are convinced that we can help Exxelia's teams by giving them the means to meet their ambitions ».